Back to today’s briefing

Story perspectives

Sarepta Gains Approval for Huntington's Disease Clinical Trial

2/6/2026

27 2

Summary

Story summary

Sarepta Therapeutics, Inc. announced that Medsafe, New Zealand's Medicines and Medical Devices Safety Authority, approved its clinical trial application for SRP-1005-101 (INSIGHTT).
The first-in-human trial will assess safety and tolerability of SRP-1005 for Huntington's Disease and is expected to begin in Q2 2026.
The study will enroll approximately 24 participants.
Investors are advised to review Sarepta's SEC filings for detailed risk factors.

1 of 1

Story summary

Sarepta Therapeutics, Inc. announced that Medsafe, New Zealand's Medicines and Medical Devices Safety Authority, approved its clinical trial application for SRP-1005-101 (INSIGHTT).
The first-in-human trial will assess safety and tolerability of SRP-1005 for Huntington's Disease and is expected to begin in Q2 2026.
The study will enroll approximately 24 participants.
Investors are advised to review Sarepta's SEC filings for detailed risk factors.